ALMS
NASDAQ · Pharmaceuticals
Alumis Inc
$7.90
+0.13 (+1.67%)
ALMS News3 articles
Alumis Stock Craters 59% on Failed Lupus Trial
Alumis shares dropped 59% after its key lupus trial failed to meet primary and secondary endpoints, erasing $1.67 billion in market value.
Alumis Stock Jumps 15.6% on Strong Analyst Support and Psoriasis Trial Results
Alumis shares jumped 15.55% on double average volume, driven by strong analyst support and late-stage psoriasis data. The company remains high-risk with no approved products.
Rare Hindenburg Omen Flashes Twice as Wall Street Divergence Widens
A rare market warning signal, the Hindenburg Omen, flashed twice on Wall Street as tech stocks surge while other sectors lag, despite the S&P 500 hitting a new high.